Latox (Nitrous Oxide, Oxygen)

Nitrous oxide exerts its effect by antagonizing NMDA receptors in the central nervous system and modulating opioid pathways, which together produce analgesia and sedation. The oxygen component ensures adequate oxygenation while the gas mixture depresses neuronal activity without causing deep cardiovascular depression at therapeutic levels.

The specific concentration and flow rate of Latox are determined by the prescribing clinician based on the procedure, patient characteristics, and monitoring requirements. Dosing is individualized and should follow the healthcare professional’s instructions and institutional protocols.

Safety data for nitrous oxide use in pregnancy are limited, and the drug is classified as category unknown. It should only be used when the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should consult their healthcare provider before exposure.

To request Latox, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with agents such as sevoflurane or desflurane, nitrous oxide provides rapid onset and recovery, modest analgesia, and minimal cardiovascular depression. It is often used as a supplemental agent rather than a sole anesthetic, whereas other inhalational agents may be used for full general anesthesia.

Latox should be stored at ambient temperature, kept upright in its cylinder, and protected from heat, direct sunlight, and physical damage. Cylinders must be secured to prevent tipping and handled according to local regulations for medical gases.

Latox is delivered via a calibrated inhalation system, such as a demand valve or a face mask, allowing the patient to inhale a controlled mixture of nitrous oxide and oxygen. Administration is performed by trained personnel who monitor the patient’s vital signs throughout the procedure.

The most serious risks include hypoxia if oxygen delivery is insufficient, severe respiratory depression, loss of consciousness, cardiovascular instability, and, rarely, methemoglobinemia or seizures. Continuous monitoring and proper equipment checks are essential to mitigate these risks.

Latox should be avoided in patients with severe chronic obstructive pulmonary disease, untreated pneumothorax, known hypersensitivity to nitrous oxide, or those who cannot be adequately monitored. It is also contraindicated in individuals where the benefits do not outweigh potential risks, such as certain high‑risk obstetric cases.